Compare Enveric Biosciences Inc (ENVB) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs DENTSPLY SIRONA Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while DENTSPLY SIRONA Inc trades at $8.67 (market cap $1.70B). The key difference: DENTSPLY SIRONA Inc is far larger — about 254.1× Enveric Biosciences Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| ENVB | XRAY | |
|---|---|---|
Market Cap | $6.69M | $1.70B |
Volume | 41,141 | 4,220,050 |
Sector | Health | Health |
52-Week High | $10.80 | $14.68 |
52-Week Low | $1.27 | $8.52 |
Typical Hold Time | 14 Days | 72 Days |
Enterprise Value | -$1.60M | $3.78B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
DENTSPLY SIRONA (XRAY) trades at $8.54, near a 52-week low, with a bearish technical signal from moving averages. The company reported a Q2 2026 earnings beat but faces declining revenues and negative net income margins. Recent news highlights institutional stake increases and ongoing turnaround efforts amid sales weakness in dental segments.
The outlook remains challenging due to persistent profitability issues and high debt, though analyst consensus suggests upside to a $13.40 price target. Key risks include margin pressure and competitive threats, while potential catalysts include successful restructuring and digital dentistry growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
